254 related articles for article (PubMed ID: 20736091)
1. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice.
Plotkin LI; Bivi N; Bellido T
Bone; 2011 Jul; 49(1):122-7. PubMed ID: 20736091
[TBL] [Abstract][Full Text] [Related]
2. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.
Bellido T; Plotkin LI
Bone; 2011 Jul; 49(1):50-5. PubMed ID: 20727997
[TBL] [Abstract][Full Text] [Related]
3. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
Weinstein RS; Jilka RL; Almeida M; Roberson PK; Manolagas SC
Endocrinology; 2010 Jun; 151(6):2641-9. PubMed ID: 20410195
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.
Plotkin LI; Gortazar AR; Davis HM; Condon KW; Gabilondo H; Maycas M; Allen MR; Bellido T
J Biol Chem; 2015 Jul; 290(31):18934-42. PubMed ID: 26085098
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies using non-traditional bisphosphonates.
Plotkin LI; Buvinic S; Balanta-Melo J
Bone; 2020 May; 134():115301. PubMed ID: 32112989
[TBL] [Abstract][Full Text] [Related]
6. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
Plotkin LI; Lezcano V; Thostenson J; Weinstein RS; Manolagas SC; Bellido T
J Bone Miner Res; 2008 Nov; 23(11):1712-21. PubMed ID: 18597631
[TBL] [Abstract][Full Text] [Related]
7. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
Weinstein RS; Chen JR; Powers CC; Stewart SA; Landes RD; Bellido T; Jilka RL; Parfitt AM; Manolagas SC
J Clin Invest; 2002 Apr; 109(8):1041-8. PubMed ID: 11956241
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice.
Weinstein RS; O'Brien CA; Almeida M; Zhao H; Roberson PK; Jilka RL; Manolagas SC
Endocrinology; 2011 Sep; 152(9):3323-31. PubMed ID: 21771887
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
Plotkin LI; Manolagas SC; Bellido T
Bone; 2006 Sep; 39(3):443-52. PubMed ID: 16627025
[TBL] [Abstract][Full Text] [Related]
10. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.
Plotkin LI; Weinstein RS; Parfitt AM; Roberson PK; Manolagas SC; Bellido T
J Clin Invest; 1999 Nov; 104(10):1363-74. PubMed ID: 10562298
[TBL] [Abstract][Full Text] [Related]
11. The role of inhibition of osteocyte apoptosis in mediating orthodontic tooth movement and periodontal remodeling: a pilot study.
Kaplan M; Kalajzic Z; Choi T; Maleeh I; Ricupero CL; Skelton MN; Daily ML; Chen J; Wadhwa S
Prog Orthod; 2021 Jul; 22(1):21. PubMed ID: 34308514
[TBL] [Abstract][Full Text] [Related]
12. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.
Aguirre JI; Plotkin LI; Stewart SA; Weinstein RS; Parfitt AM; Manolagas SC; Bellido T
J Bone Miner Res; 2006 Apr; 21(4):605-15. PubMed ID: 16598381
[TBL] [Abstract][Full Text] [Related]
13. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
Weinstein RS; Jilka RL; Parfitt AM; Manolagas SC
J Clin Invest; 1998 Jul; 102(2):274-82. PubMed ID: 9664068
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.
O'Brien CA; Jia D; Plotkin LI; Bellido T; Powers CC; Stewart SA; Manolagas SC; Weinstein RS
Endocrinology; 2004 Apr; 145(4):1835-41. PubMed ID: 14691012
[TBL] [Abstract][Full Text] [Related]
16. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue.
Cardoso L; Herman BC; Verborgt O; Laudier D; Majeska RJ; Schaffler MB
J Bone Miner Res; 2009 Apr; 24(4):597-605. PubMed ID: 19049324
[TBL] [Abstract][Full Text] [Related]
17. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.
Jia D; O'Brien CA; Stewart SA; Manolagas SC; Weinstein RS
Endocrinology; 2006 Dec; 147(12):5592-9. PubMed ID: 16935844
[TBL] [Abstract][Full Text] [Related]
19. The effects of mechanically loaded osteocytes and inflammation on bone remodeling in a bisphosphonate-induced environment.
George EL; Truesdell SL; Magyar AL; Saunders MM
Bone; 2019 Oct; 127():460-473. PubMed ID: 31301402
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid-Induced Bone Fragility Is Prevented in Female Mice by Blocking Pyk2/Anoikis Signaling.
Sato AY; Cregor M; McAndrews K; Li T; Condon KW; Plotkin LI; Bellido T
Endocrinology; 2019 Jul; 160(7):1659-1673. PubMed ID: 31081900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
